Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2a study of BMS-986207 alone and with nivolumab in advanced solid tumors
jRCT2080223478Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of BMS-986207 and nivolumab in Nonhematologic neoplasms (2 arms), sponsored by Bristol Myers Squibb. Started Mar 2017; status: completed.
02
Drugs
BMS-986207nivolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080223478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223478.